Helen Won

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia

  Blood · 2025-10-07 · 5 citations

• [Biological Differences between EGFR ex19del and ex21L858R-Preclinical Models Using an Engineered Pair of Isogenic NSCLC Cell Lines with CRISPR Engineering].

  PubMed · 2025-09-01

• Abstract P1-01-26: Genomic profiling of ctDNA & assoc. w/ efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy

  Clinical Cancer Research · 2025-06-13

• POS0718 SINGLE-CELL RNA SEQUENCING HIGHLIGHTS THE ROLE OF INNATE IMMUNITY IN IDENTIFYING CANDIDATES FOR EARLY BIOLOGICS TREATMENT IN AXIAL SPONDYLOARTHRITIS

  Annals of the Rheumatic Diseases · 2025-06-01

• 6MO Baseline ctDNA and methylation status as predictors of treatment benefit in the phase III post MONARCH trial of abemaciclib + fulvestrant in advanced breast cancer patients

  ESMO Open · 2025-05-01

• P008: Prognostic Utility of ctDNA Detection in The monarchE Trial of Adjuvant Abemaciclib Plus Endocrine therapy (ET) in HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC)

  The Breast · 2025-02-01

• P002: Genomic And Transcriptomic Profiling of Primary Tumors From Patients with HR+, HER2-, Node-positive, High-risk Early Breast Cancer (EBC) in the monarchE Trial

  The Breast · 2025-02-01